Blog Category

Tag: Millendo Therapeutics

Navigate all the resources featured in the Landscape Guide by geographic location, industry sector, and organization type. Landscape Guide
Everything you need to know to make a meaningful first connection can be found in our 2021-22 Landscape Guide! Download the Guide

2023 MVCA Research Report

Our state's entrepreneurial economy hinges on our ability to provide capital to our high-growth, high-potential companies. Download the Report
October 05 Millendo Therapeutics, Capital Event of the Year!

Finding drugs to improve the quality of life for patients with endocrine diseases with few or no treatment options, can be a noble but resource-intensive task.  For Ann Arbor-based Millendo Therapeutics, a $62 million Series B financing announced in January 2016 moved the biotechnology company a little closer to that goal and earned it the […]


Read More
January 05 Member News: Millendo Licenses Phase 2 from AstraZeneca and Secures Series B Financing of $62 Million

ANN ARBOR, Mich., Jan. 5, 2016 – Millendo Therapeutics, Inc., today announced that it has entered into an exclusive license agreement with AstraZeneca for the worldwide development and commercialization rights to AZD4901, a product candidate for the treatment of polycystic ovary syndrome (PCOS), the most common endocrine disease in women. The Company will develop the […]


Read More